DBV Technologies S.A. (NASDAQ:DBVT) Receives $48.50 Consensus Price Target from Analysts

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have earned an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $48.50.

Several equities analysts have commented on the stock. Weiss Ratings downgraded shares of DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 17th. Wall Street Zen cut DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Citizens Jmp increased their price target on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research report on Tuesday, June 30th. Cantor Fitzgerald reissued an “overweight” rating on shares of DBV Technologies in a research report on Thursday, September 10th. Finally, HC Wainwright reiterated a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th.

DBV Technologies Stock Performance

Shares of DBVT stock opened at $12.63 on Friday. DBV Technologies has a fifty-two week low of $8.85 and a fifty-two week high of $26.18. The company has a 50 day moving average price of $13.71 and a 200 day moving average price of $17.07. The stock has a market capitalization of $794.17 million, a P/E ratio of -3.60 and a beta of -0.95.

Hedge Funds Weigh In On DBV Technologies

Several large investors have recently bought and sold shares of the business. Allworth Financial LP acquired a new stake in shares of DBV Technologies during the 4th quarter worth about $32,000. Royal Bank of Canada raised its holdings in DBV Technologies by 167.1% during the first quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock worth $98,000 after purchasing an additional 2,928 shares in the last quarter. Cetera Investment Advisers raised its holdings in DBV Technologies by 93.4% during the first quarter. Cetera Investment Advisers now owns 25,358 shares of the company’s stock worth $530,000 after purchasing an additional 12,243 shares in the last quarter. Personal CFO Solutions LLC purchased a new stake in shares of DBV Technologies during the 1st quarter worth approximately $264,000. Finally, AdvisorShares Investments LLC purchased a new stake in shares of DBV Technologies during the 1st quarter worth approximately $1,052,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s lead technology, Viaskin, is designed to deliver targeted immunotherapy through the skin without requiring an injection. Its approach is intended to expose the immune system to controlled amounts of an allergen while limiting systemic exposure.

DBV Technologies’ primary product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.